The short version of triple agonist fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-04-15. Anything still debated is marked as such rather than presented as settled.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
| Property | Value | Notes |
|---|---|---|
| Receptor targets | GIP, GLP-1, glucagon | One molecule activates all three pathways |
| Research identifier | LY3437943 | Code used in published trial reports |
| Development stage | Phase 3, reported as ongoing | Not approved by any regulatory agency |
| Route studied | Subcutaneous | Administration form used in clinical trials |
| Studied populations | Adults with obesity or type 2 diabetes | Enrollment criteria vary between trials |
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
If not among 7.7 billion." Since 2013, Reporters Without Borders, an international non-profit and non-governmental organization with the stated aim of safeguarding the right to freedom of information, included Xi among the list of press freedom predators.
=== Bacterial homeostasis === AMPylation is involved in bacterial homeostasis. The most famous example is AMPylator GS-ATase (GlnE), which contributes in complex regulation of nitrogen metabolism through AMPylation of glutamine synthetase that was introduced in the AMPylation and DeAMPylation parts. Another example of AMPylators that play a role in bacterial homeostasis is the class I Fic AMPylators (FicT), which modifies the GyrB subunit of DNA gyrase, the conserved tyrosine residue for ATP binding of ParE subunit at Topoisomerase IV. This DNA gyrase inactivation by AMPylation leads to the activation of SOS response, which is the cellular response to DNA damage. The activity of FicT AMPylation is reversible and only leads to growth arrest, but not cell death. Therefore, FicT AMPylation plays a role in regulating cell stress, which is shown in the Wolbachia bacteria that the level of FicT increases in response to doxycycline. A Class III Fic AMPylator NmFic of N. meningtidis is also found to modify AMPylate GyrB at the conserved tyrosine for ATP binding. This shows that Fic domains are highly conserved that indicates the important role of AMPylation in regulating cellular stress in bacteria. The regulation of NmFic involves the concentration-dependent monomerization and autoAMPylation for activation of NmFic activity.
=== Dosage === Adult: Each tablet contains flupentixol 0.5 mg and melitracen 10 mg. The usual adult dose is one tablet in the morning and one at midday; in severe cases the morning dose may be increased to two tablets. The maximum recommended dose is four tablets per day. Elderly: The usual starting dose is one tablet in the morning; in severe cases, one tablet may also be given at midday.
Sources: en.wikipedia.org
=== As an invasive species === Japanese honeysuckle has become naturalized in Argentina, Australia, Brazil, Mexico, New Zealand, and much of the United States, including Hawaii, as well as a number of Pacific and Caribbean islands. It is classified as a noxious weed in 46 states, being prohibited to be bought and sold in Connecticut, Illinois, Massachusetts, and Vermont, and banned in Indiana and New Hampshire. It is on the New Hampshire invasive species list. Lonicera japonica was initially brought to the U.S. from Japan in the early 1800s as an ornamental plant. It is still deliberately planted in the U.S. for reasons such as erosion control or forage for deer, but has become invasive in many areas. It prefers to invade areas that have been disturbed, such as roadsides or floodplains. It will generally only invade forests when the canopy has been opened by logging or fallen trees, as it grows less vigorously in the shade. Once it has invaded an area, Lonicera japonica grows rapidly and outcompetes native plants for sunlight and nutrients. It proliferates using both sexual and vegetative reproduction, producing seeds that are spread by animals and expanding locally via rhizomes. Eventually, it will form a dense thicket which prevents other plant species from germinating in that area. Due to its suppression of germination in the understory, Lonicera japonica also prevents the regeneration of trees.
== In-house writers == Tania Carmenatti, Dana Meyers, Dennis "Den Den" Nelson, Dynasty members Nidra Beard & William Shelby, The Time member Ricky Darnell "Freeze" Smith, The Sylvers member Charmaine Sylvers, and Johnny Thomas Jr. were frequent writing collaborators on various SOLAR albums and/or for various SOLAR acts. Credits are courtesy of Tidal and Spotify. (A majority of Beard and Shelby's written contributions to their own group are omitted)
From the late 1950s through the late 1970s, ant farms were popular educational children's toys in the United States. Some later commercial versions use transparent gel instead of soil, allowing greater visibility at the cost of stressing the ants with unnatural light.
Sources: en.wikipedia.org
From the sophistication of full fentanyl synthesis and acute toxicity in laboratory environments, 'clandestine' labs in Mexico prefer to make an illicit dosage form from available fentanyl rather than the synthesis itself. Based on further research by investigators, fentanyl and analogues are likely synthesized in labs that have the appearance of a legal entity, or are diverted from pharmaceutical laboratories. Investigations and convictions of members of the Sinaloa drug cartel by federal agencies made a clear connection between illegal arms trafficking from the U.S. to Mexico and the smuggling of fentanyl into the U.S. Mexico had repeatedly made official complaints, since illegal guns are easily purchased (for example in Arizona and as far north as Wisconsin and even Alaska) according to U.S. intelligence sources. The guns are transported onto Mexican territory through a chain of American brokers and couriers, often financed by those drug cartels that also engage in money laundering. Therefore, the lack of arms controls in the U.S. has directly contributed to the U.S. opioid overdose crisis. The opioid epidemic in the United States is largely fueled by drugs smuggled from Mexico; approximately 98% of fentanyl entering the U.S. comes from Mexico. In January 2025, President Trump said that tariffs on Mexico were intended to reduce the U.S. trade deficit and force the country to secure its border with the U.S. against fentanyl smuggling and illegal immigration.
=== Rivalries === A strong athletic rivalry exists between the University of Arizona and Arizona State University in Tempe, Arizona. The University of Arizona leads the all-time record against Arizona State University in men's basketball (149–83), as well as in football (49–42–1). The football rivalry game between the schools is known as "The Duel in the Desert". The trophy awarded after each game is the Territorial Cup. Rivalries have also been created with other Pac-12 teams, especially the University of California, Los Angeles which has proved to be a worthy softball rival and was Arizona's main basketball rival for most of 1990s.
The Dharampal Satyapal Group (DS Group) is a privately held Indian FMCG conglomerate. Established in 1929, and headquartered in Noida, Uttar Pradesh. The company operates across multiple sectors including food and beverages, confectionery, tobacco, hospitality, and luxury retail.
=== Storage methods === Fresh refrigerated tempeh should be sealed in a labeled polyethylene bag and kept in temperatures below 4 °C (40 °F). It can be kept at this temperature for three to five days and sometimes, even as long as a week. Storage life could be extended to two or three weeks if the tempeh is blanched or steamed prior to refrigeration due to the inactivation of enzymes and destruction of bacteria. Freezing is the preferred way to preserve tempeh due to its capability for wide distribution. Tempeh can be frozen whole or in slices, depending on preference. During the freezing process, whole tempeh is placed in its perforated wrapper whereas sliced tempeh is packaged in a labelled polyethylene bag prior to being sealed in an outer bag and then frozen immediately. This method will keep for months with only a small loss of texture and flavor. Blanching tempeh by steaming or parboiling helps to extend the storage life by preventing bacterial growth, stopping mold growth and inactivating enzymes. Steaming appears to have a less negative effect than parboiling in terms of texture, flavor and nutritional value. Blanching is a great method for preserving tempeh prior to refrigeration, though not as beneficial for tempeh that is to be frozen.
Sources: en.wikipedia.org
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.
No regulatory agency has approved it for any indication. It remains an investigational product studied within controlled clinical trial programs.
A dual agonist engages two receptor targets, typically GIP and GLP-1. A triagonist adds glucagon receptor activity, which is intended to influence energy expenditure alongside appetite and glucose handling.
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.